Clinical Features, Prognostic Factors and Outcome of Children with Ewing Sarcoma: A Single-center Experience

• DOI: 10.4274/jcp.2023.46667
• Publication Date: 2023-04-14T11:30:35Z
• Authors: Işık Odaman Al; Bengü Demirağ; Dündar Sabah; Serra Kamer; Başak Doğan Avşargil; Mehmet Argın; Yeşim Oymak
• Keywords: Center (category theory); Single Center; Ewing's sarcoma

Introduction: Ewing sarcoma (ES) is a rare, aggressive, malignant tumor.It the second most common bone tumor in children.A total of 20-25% patients are metastatic at time diagnosis.The survival rate for localized disease (LD) approximately 70-74%.For (MD), it about 30%.The important prognostic factor affecting presence MD diagnosis.In this study, we investigated clinical characteristics, treatment outcome, and factors prognosis followed up with diagnosis ES. Materials Methods: Between 2007 2020, 24 ES aged 0-18 years were retrospectively analyzed. Results:The complaint was pain swelling lesion area (n=9), by (n=5), (n=3), abdominal (n=2), shortness breath facial paralysis (n=1), spinal compression findings (leg walking difficulty) (n=1) hematuria (n=1).ES bone-derived 19 (79%).Of these, 14 had LD 5 diagnosis.Extraskeletal sarcomas (EES), detected five (21%) derived from kidney rectus abdominis left quadriceps femoris muscle upper thoracic region lumbar paraspinal muscles (n=2).The 25% (6/24) entire patient group.Disease progression observed three during treatment.Relapse follow-up 6 complete remission.The median to relapse 20 months (minimum 13, maximum 34 months) our after 14.5 6-maximum 27 months).Radiological response histopathological induction therapy, or progression, site found be correlated (Fisher's Exact test p=0.02,0.0047, <0.001, 0.001 respectiveley).Conclusion: cancer high mortality morbidity.Although symptoms swelling, may vary depending on which originates.Response therapy relapse-progression prognosis.Treatment should personalized improve survival.